|
|
|
|
| Interview |
 |
|
Seizing the Opportunity in Europe: Bruno Wohlschlegel |
Bruno Wohlschlegel, European head of Merck KGaA, Darmstadt, Germany's Healthcare business, outlines the highlights of his career and talks about how his vision for Europe draws strength from the region’s diversity to advance collaboration and progress
… Read more |
|
|
| Special Feature |
 |
|
Pharm Exec’s Top 50 Companies 2019 |
Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market
… Read more |
|
|
|
| Outcomes-Based Contracting |
 |
|
The Next Steps to Better Patient Care |
While there are challenges at every turn, the promise of outcomes-based contracting is a level of care for patients that might otherwise not be possible, while striking the right balance of benefits and risks for all parties involved, writes Melonie Warfel
… Read more |
|
|
|
| Audio |
 |
|
|
|
|
| Calendar |
|
|
| Industry update |
| //
Professor Peter Johnson has been appointed as the new Chief Medical Officer for Cancer Research UK’s Centre for Drug Development. Professor Johnson previously served as Cancer Research UK’s chief clinician for 10 years.
//
ReViral (Londom, UK) announced that Alex C. Sapir has been appointed Chief Executive Officer and elected to the Board of Directors. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer.
//
NeoPhore (Cambridge, UK) named Dr. Matthew Baker as VP Immunology.
//
Valo Therapeutics (Oxford, UK, and Helsinki, Finland) appointed Dr. Michael Stein to the full-time role of Chief Executive Officer, having served as part-time co-Chairman since the company’s inception in January 2017.
//
Axovant Gene Therapies (Basel, Switzerland) appointed David Nassif as Chief Financial Officer.
|
|
|
|
|
|
|
|
|
